Trial Profile
Durvalumab (MEDI4736) Plus Tremelimumab in Resectable, Locally Advanced Squamous Cell Carcinoma of the Oral Cavity: a Window of Opportunity Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DUTRELASCO
- 06 Jun 2023 Results assessing the safety and efficacy of durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2022 Planned primary completion date changed from 31 Mar 2020 to 24 Mar 2023.
- 01 Feb 2022 Planned End Date changed from 31 Mar 2022 to 24 Mar 2026.